What Is Cumberland Pharmaceuticals Inc. (CPIX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Cumberland Pharmaceuticals Inc.'s intrinsic value is estimated at $4.08. Trading at its current price of $7.80, the valuation engine raises significant caution: 10 of 12 models flag downside risk, projecting an average implied return of -47.7%. Model dispersion is worth noting: RCMH-DCF targets $10.80 (+38.5%), versus First Chicago at $0.47 (-94.0%). This +132.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About CPIX?
12 of 13 models are currently active for CPIX. Of these, 2 models suggest upside while 10 models suggest overvaluation. The Bayesian DCF estimates CPIX's intrinsic value at $1.45, implying -81.4% downside from the current price. See which stocks rank higher →
How Does CPIX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, CPIX ranks #104 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Cumberland Pharmaceuticals Inc.'s positioning within the Pharmaceutical Preparations segment means that biosimilar competition timeline plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.
Is CPIX a Value Trap?
CirclFi's Value Trap algorithm assigns CPIX a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Cumberland Pharmaceuticals Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Cumberland Pharmaceuticals Inc. earns a quality score of 6.3/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +132.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CPIX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CPIX's 12 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad